{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:08:32Z","timestamp":1790078912888,"version":"4.0.1"},"reference-count":32,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Lipoprotein apheresis (LA) remains an important treatment option for patients with homozygous familial hypercholesterolemia (HoFH) who have persistently severe low- density lipoprotein cholesterol (LDL-C) elevation despite intensive lipid-lowering therapy. Therapeutic plasma exchange (TPE) may serve as a temporary alternative when selective LA is unavailable. Methods: This retrospective, single-center longitudinal observational study evaluated six patients with HoFH treated with double-filtration plasmapheresis (DFPP) between 2010 and 2023. During a temporary interruption in DFPP availability, two patients underwent TPE. Pre- and post-procedure lipid levels were evaluated using paired measurements. Results: A total of 476 DFPP and 20 TPE procedures were performed. During DFPP, the median reductions in total cholesterol and LDL-C were 64.44% [57.14\u201370.21] and 67.53% [59.53\u201373.86], respectively, while the median reductions in high-density lipoprotein cholesterol (HDL-C) and triglycerides were 40.00% [30.63\u201348.00] and 48.63% [35.38\u201357.66]. Among TPE procedures with paired measurements, the corresponding median reductions were 71.11% [65.52\u201372.69] for total cholesterol, 70.97% [67.14\u201373.72] for LDL-C, 67.08% [62.92\u201370.83] for HDL-C, and 55.73% [38.68\u201363.33] for triglycerides. No serious adverse events were observed during DFPP. TPE was discontinued in one patient after chills and subfebrile fever. Conclusions: Long-term DFPP was associated with substantial acute lipid reductions in patients with HoFH. TPE also produced marked acute lipid reductions in two patients when DFPP was unavailable. However, the limited number of TPE-treated patients, repeated procedures within the same individuals, and overlapping evolocumab exposure preclude conclusions regarding comparative efficacy or safety. TPE may be considered as an individualized interim option when selective lipoprotein apheresis is temporarily unavailable.<\/jats:p>","DOI":"10.3390\/jcm15187233","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:09:35Z","timestamp":1790075375000},"page":"7233","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-9388","authenticated-orcid":false,"given":"Filiz","family":"Mercan Sar\u0131da\u015f","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-6282","authenticated-orcid":false,"given":"Canan","family":"Ersoy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-134X","authenticated-orcid":false,"given":"Fahir","family":"\u00d6zkalemka\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Haematology, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Hocao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"M\u00fcge","family":"Ya\u015far","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-9539","authenticated-orcid":false,"given":"Kadircan","family":"Karatoprak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-4165","authenticated-orcid":false,"given":"\u00d6zen","family":"\u00d6z G\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Soner","family":"Cander","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Erdin\u00e7","family":"Ert\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, Bursa Uluda\u011f University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: Retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: New treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_4","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993\u20132026). Familial Hypercholesterolemia. GeneReviews\u00ae, University of Washington, Seattle. updated 30 January 2025."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","article-title":"Homozygous Familial Hypercholesterolemia Treatment: New Developments","volume":"27","author":"Blom","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MOL.0000000000000784","article-title":"Use of apheresis in the age of new therapies for familial hypercholesterolaemia","volume":"32","author":"Thompson","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00467-022-05541-1","article-title":"An update on lipid apheresis for familial hypercholesterolemia","volume":"38","author":"Taylan","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_11","first-page":"444","article-title":"The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating","volume":"33","author":"Stefanutti","year":"2012","journal-title":"G. Chir."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","article-title":"The German Lipoprotein Apheresis Registry (GLAR)\u2014Almost 5 years on","volume":"12","author":"Schettler","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989\u20132017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000497447","article-title":"Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction","volume":"47","author":"Raina","year":"2019","journal-title":"Blood Purif."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolaemia","volume":"1","author":"Thompson","year":"1975","journal-title":"Lancet"},{"key":"ref_16","first-page":"197","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"Alquist","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_19","first-page":"32","article-title":"LDL apheresis in the treatment of familial hypercholesterolemia","volume":"42","author":"Coker","year":"2014","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5603\/CJ.a2018.0100","article-title":"Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre","volume":"26","author":"Mickiewicz","year":"2019","journal-title":"Cardiol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","article-title":"LDL Apheresis and Lp (a) Apheresis: A Clinician\u2019s Perspective","volume":"23","author":"Kayikcioglu","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.transci.2018.11.007","article-title":"The efficacy of double filtration plasmapheresis in the treatment of homozygous familial hypercholesterolemia: A single-center experience","volume":"58","author":"Albayrak","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.transci.2015.10.015","article-title":"Long-term efficacy of lipoprotein apheresis in the management of familial hypercholesterolaemia: Application of two different apheresis techniques in childhood","volume":"54","author":"Gokay","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"ref_24","first-page":"585","article-title":"Lipoprotein apheresis in patients with familial hypercholesterolemia: A single center research","volume":"50","author":"Zhao","year":"2022","journal-title":"Zhonghua Xin Xue Guan Bing. Za Zhi"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.htct.2021.01.009","article-title":"Lipoprotein apheresis efficacy and challenges: Single center experience","volume":"44","author":"Ozdemir","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/1744-9987.13857","article-title":"Beyond cholesterol-pleiotropic effects of lipoprotein apheresis","volume":"26","author":"Schettler","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.transci.2004.01.008","article-title":"Lipidfiltration--safe and effective methodology to perform lipid-apheresis","volume":"30","author":"Klingel","year":"2004","journal-title":"Transfus. Apher. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-Term Evolocumab in Patients With Familial Hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jacl.2021.10.003","article-title":"Evolocumab in patients with homozygous familial hypercholesterolemia in India","volume":"15","author":"Bansal","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1074248420943079","article-title":"Lipoprotein Apheresis and Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study","volume":"26","author":"Kolovou","year":"2021","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","article-title":"Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Hovingh","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jca.21294","article-title":"Effect of therapeutic plasma exchange on coagulation parameters in patients on warfarin","volume":"29","author":"Zantek","year":"2014","journal-title":"J. Clin. Apher."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7233\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:23:56Z","timestamp":1790076236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187233"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187233","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}